New Treatment Option Available for Fabry Disease – 5/25/2023

[et_pb_section fb_built=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.20.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_code _builder_version=”4.20.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] /* OUTLOOK-SPECIFIC STYLES */ li { text-indent: -1em; padding: 0; margin: 0; /* line-height: 1.2; Remove after testing */ } ul, ol { padding: 0; margin: 0 0 0 40px; } p { margin: 0; padding: 0; margin-bottom: 0; } New Treatment Option Available for Fabry Disease

Dear Payer,

 

We are pleased to announce the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj); a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease.1

Dosage and Administration1:

  • The recommended dosage is 1 mg/kg administered every 2 weeks as an intravenous infusion for appropriate patients
  • Elfabrio must be diluted prior to use; initial infusion time is as little as 3 hours
  • Home administration under the supervision of a healthcare provider may be considered for maintenance infusions

Ordering Information:

Elfabrio will solely be available through Eversana Life Sciences Specialty Pharmacy.

Product Description

NDC #

Package Size

Elfabrio® (pegunigalsidase alfa-iwxj)

10122-160-02

1 single-dose/10-mg vial

Elfabrio® (pegunigalsidase alfa-iwxj)

10122-160-05

5 single-dose/10-mg vial

Elfabrio® (pegunigalsidase alfa-iwxj)

10122-160-10

10 single- dose/10-mg vial


For more information, please contact:


Your Chiesi Rare Disease National Account Directors:


Garrick Campbell Garrick.Campbell@chiesi.com



Tim Hambacher

Tim.Hambacher@chiesi.com



Lee Stout

Government – DoD, VA, Medicaid

Lee.Stout@chiesi.com

Eversana

(Via Chiesi Total CareSM)


www.chiesitotalcare.com



Phone: (833)656-1056

Fax: (636) 355-3610

Medical Information


Phone: (888) 661-9260

Fax: (866) 443-3092


Email:

us.medical@chiesi.com


Or visit www.elfabrio.com


Indication

Elfabrio® (pegunigalsidase alfa-iwxj) is indicated for the treatment of adults with confirmed Fabry disease.

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS


Patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Elfabrio administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue Elfabrio immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Elfabrio may be considered.

Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and infusion-associated reactions (IARs), and instruct them to seek medical care immediately if such symptoms occur.

  • If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Elfabrio administration and initiate appropriate medical treatment.
  • If a mild to moderate hypersensitivity reaction or IAR occurs, consider slowing the infusion rate or temporarily withholding the dose.


In clinical trials, 41 (29%) Elfabrio-treated patients experienced one or more infusion-associated reactions, including hypersensitivity, nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension.

 

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If glomerulonephritis is suspected, discontinue treatment until a diagnostic evaluation can be conducted.

 

When switching to Elfabrio from a prior enzyme replacement therapy, the risk of hypersensitivity reactions and infusion-associated reactions may be increased in certain patients with pre-existing anti-drug antibodies (ADAs). Consider monitoring IgG and IgE ADAs and clinical or pharmacodynamic response (eg, plasma lyso-Gb3 levels).

 

The most common adverse reactions (≥15%) were infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.



Reference: 1. Elfabrio [prescribing information]. Cary, NC: Chiesi USA, Inc.; 2023.


Please see Full Prescribing Information for Elfabrio.

©Chiesi USA, Inc. 2023. All rights reserved.

Elfabrio® is a registered trademark of CHIESI FARMACEUTICI S.p.A.

Chiesi Total CareSM is a service mark of CHIESI FARMACEUTICI S.p.A.

PP-EF-0314 V1.0